• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Olympus recommends removal of discontinued insufflation units

Olympus recommends removal of discontinued insufflation units

January 26, 2026 By Sean Whooley

This image shows the logo of Olympus.The FDA issued an early alert after Olympus issued a letter recommending the removal of certain High Flow Insufflation Units.

To notify the public of a potentially high-risk device issue, the FDA’s Center for Devices and Radiological Health issued the alert after Olympus told affected customers to consider removing affected devices from where they are used or sold.

Insufflation units insufflate the abdominal cavity and provide automatic suction and smoke evacuation. They help to facilitate laparoscopic observation and treatment.

Olympus’ warning stated that the software algorithm on its High Flow Insufflation Unit (models UHI, UHI-2 and UHI-3) requires correction. The company said it needs to address a potential issue that could lead to overpressure events. It previously discontinued the affected products and they haven’t been supported by repair for “many years,” according to the FDA alert. As a result, Olympus said it decided to remove these devices from the market.

In 2023, the company instructed customers to discontinue use of the UHI-4 regarding issues related to over-insufflation until corrective actions were identified and implemented. In 2025, the issues identified in that field correction action were addressed, and updated devices have been returned to clinical use.

Over-insufflation can lead to a number of patient harms during a procedure. Those include air embolism, arrythmias (bradycardia, asystole, or cardiac arrest), pneumothorax, kidney or urinary problems, hypoxia, subcutaneous emphysema, delay to treatment, more complex procedures and potentially death. The company reports two serious injuries and no deaths associated with the issue.

On Jan. 16, Olympus told affected customers to examine inventory and quarantine any identified devices immediately. Customers should immediately cease usage of any affected models in their inventory.

 

This article previously stated that Olympus discontinued the UHI-4. The company instructed users to discontinue use until corrective actions were identified and implemented. This has been updated.

Filed Under: Business/Financial News, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance, Surgical Tagged With: Olympus

More recent news

  • Olympus receives FDA warning letter after international inspections
  • Stryker dives into soft-tissue robotics with $400M play for CMR Surgical’s Versius
  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy